Rheumatology Update Europe 2026

Vienna & Virtual, 17 – 18 April, 2026

Industry Partners

med update europe GmbH

unbiased support by

Boehringer Ingelheim

Boehringer Ingelheim is driven by the desire to serve humankind by improving human and animal health. As a successful, family owned company BI plans in generations. They work together globally and with integrity.

Transparency Notes

Boehringer Ingelheim is a partner of the Rheumatology Update Europe 2026.

Symposium:

Joint decisions between rheumatology and pulmonology: A multidisciplinary approach to CTD-ILD

Speakers:

Thomas Koudstaal, The Netherlands
Jeska de Vries-Bouwstra, The Netherlands

17 April, 2026
13:45 – 14:30

The educational content is independent from direct industry sponsorship, financially supported through an unrestricted educational grant.

This symposium is free and open to all HCPs. No congress registration required — just create an account on the linked platform to join.

GSK
Transparency Notes

Lilly is partner of the Rheumatology Update Europe 2026.

Our job is to put health above all.

Our research focuses on developing life-changing medicines for everyone, regardless of their condition’s prevalence or complexity. And we know our biggest advancements are still ahead of us.

GSK
Transparency Notes

Novartis is partner of the Rheumatology Update Europe 2026.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

GSK
Transparency Notes

Sanofi is partner of the Rheumatology Update Europe 2026.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

GSK
Transparency Notes

UCB Pharma GmbH is partner of the Rheumatology Update Europe 2026.

UCB Pharma GmbH is the Austrian subsidiary of the Belgian company UCB S.A., a globally leading biopharmaceutical company. UCB is dedicated to the research, development, and commercialization of innovative pharmaceutical and biotechnological products in the fields of neurology, immunology, and internal medicine.

Sponsorship Opportunities

Partnership Opportunities

If you are interested, please contact us directly:
c.weidenfeller@medupdate-europe.com

Extra Features

VIDEO-ON-DEMAND

Rheumatology Update Europe lectures on-demand!

All sessions are available on-demand 6 weeks after the event.
Only registered delegates enjoy exclusive access to the full on-demand program.

Revisit expert insights, watch session highlights again, or catch up on anything you missed — anytime, at your convenience.

Your event ticket is the key to this knowledge advantage.

5

ABSTRACTS

Share your work…
The Rheumatology Update Europe gives young rheumatologists, and experienced ones, an excellent opportunity to present their recent research to an interested and knowledgeable audience.

Scientific Board & Speakers